{"entity":{"id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","aka":[],"tldr":"A phase 2 trial of Telisotuzumab vedotin in non-small-cell lung cancer and small-cell lung cancer, run by AbbVie, now recruiting.","summary":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06568939 by AbbVie, with 150 participants planned, started 2025-01-20 and due to reach its primary completion in 2028-02. Interventions recorded: Telisotuzumab Vedotin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06568939","url":"https://clinicaltrials.gov/study/NCT06568939"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","met-altered-nsclc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["telisotuzumab-vedotin"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06568939","phase":"2","setting":"A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"AbbVie","started":"2025-01-20","startedType":"actual","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06568939/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}